Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes. (PubMed, Ann Hematol) - Apr 2, 2026 - "The cumulative CMV reactivation incidence rates at day 100 were 5.9% (95%CI: 1.0%-17%) and 43% (29%-55%) in the letermovir and non-letermovir groups (p = 0.012). These findings suggest letermovir helped the suppression of CMV reactivation and improved the outcome of allo-SCT with ATG by lowering relapse."
Journal • Retrospective data • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
|
|
Fumiya Ohara; Hiroya Wakabayashi; Hitomi Sawa; Kenta Motegi; Kotaro Miyao; Masashi Sawa; Shuto Negishi; Yuichiro Inagaki
|